About CCAAT/enhancer-binding protein zeta
CCAAT/enhancer-binding protein zeta (CEBPZ) is a protein
from Homo sapiens identified by UniProt accession
Q03701, 1054 residues long.
MolForge cross-references it against 0 known binders and
162 disease associations.
Target properties
| Protein name | CCAAT/enhancer-binding protein zeta |
|---|
| UniProt accession | Q03701 |
|---|
| Gene | CEBPZ |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1054 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (162)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.48
- neutrophil count · score 0.15
- Alzheimer disease · score 0.14
- neutrophil percentage of leukocytes · score 0.14
- schizophrenia · score 0.14
- acute myeloid leukemia · score 0.12
- hypertension · score 0.11
- lymphocyte percentage of leukocytes · score 0.10
- blood pressure · score 0.10
- mean corpuscular volume · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q03701-F1 | alphafold | PREDICTED | 67.02 | — |
Amino-acid sequence (1054 residues)
MAAVKEPLEF HAKRPWRPEE AVEDPDEEDE DNTSEAENGF SLEEVLRLGG TKQDYLMLAT LDENEEVIDG GKKGAIDDLQ QGELEAFIQN LNLAKYTKAS LVEEDEPAEK ENSSKKEVKI PKINNKNTAE SQRTSVNKVK NKNRPEPHSD ENGSTTPKVK KDKQNIFEFF ERQTLLLRPG GKWYDLEYSN EYSLKPQPQD VVSKYKTLAQ KLYQHEINLF KSKTNSQKGA SSTWMKAIVS SGTLGDRMAA MILLIQDDAV HTLQFVETLV NLVKKKGSKQ QCLMALDTFK ELLITDLLPD NRKLRIFSQR PFDKLEQLSS GNKDSRDRRL ILWYFEHQLK HLVAEFVQVL ETLSHDTLVT TKTRALTVAH ELLCNKPEEE KALLVQVVNK LGDPQNRIAT KASHLLETLL CKHPNMKGVV SGEVERLLFR SNISSKAQYY AICFLNQMAL SHEESELANK LITVYFCFFR TCVKKKDVES KMLSALLTGV NRAYPYSQTG DDKVREQIDT LFKVLHIVNF NTSVQALMLL FQVMNSQQTI SDRYYTALYR KMLDPGLMTC SKQAMFLNLV YKSLKADIVL RRVKAFVKRL LQVTCQQMPP FICGALYLVS EILKAKPGLR SQLDDHPESD DEENFIDAND DEDMEKFTDA DKETEIVKKL ETEETVPETD VETKKPEVAS WVHFDNLKGG KQLNKYDPFS RNPLFCGAEN TSLWELKKLS VHFHPSVALF AKTILQGNYI QYSGDPLQDF TLMRFLDRFV YRNPKPHKGK ENTDSVVMQP KRKHFIKDIR HLPVNSKEFL AKEESQIPVD EVFFHRYYKK VAVKEKQKRD ADEESIEDVD DEEFEELIDT FEDDNCFSSG KDDMDFAGNV KKRTKGAKDN TLDEDSEGSD DELGNLDDDE VSLGSMDDEE FAEVDEDGGT FMDVLDDESE SVPELEVHSK VSTKKSKRKG TDDFDFAGSF QGPRKKKRNL NDSSLFVSAE EFGHLLDENM GSKFDNIGMN AMANKDNASL KQLRWEAERD DWLHNRDAKS IIKKKKHFKK KRIKTTQKTK KQRK
Explore CCAAT/enhancer-binding protein zeta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets